camrelizumab plus vinorelbine

Camrelizumab plus vinorelbine is a combination therapy that has been studied in several clinical trials, particularly for non-small cell lung cancer (NSCLC) and other cancers. This combination pairs an immune checkpoint inhibitor (camrelizumab) with a chemotherapeutic agent (vinorelbine). ## Drug Components Camrelizumab is an anti-PD-1 monoclonal antibody that works by blocking the interaction between PD-1 and its ligands, thereby enhancing T-cell immune responses against cancer cells. It has shown encouraging efficacy in NSCLC as demonstrated in the CameL and CameL-sq studies[8]. Vinorelbine is a semi-synthetic vinca alkaloid that acts as an antimitotic agent by inhibiting microtubule assembly, thus preventing cell division. It can be administered both intravenously and orally, with the oral form (vinorelbine tartrate capsules) offering a more convenient administration option[6][7]. ## Clinical Development The combination has been investigated in several clinical settings: 1. **Elderly NSCLC Patients**: A phase II trial evaluated camrelizumab plus metronomic oral vinorelbine (mOV) as first-line therapy for Chinese elderly patients (≥70 years) with advanced NSCLC who had no positive EGFR mutation, ALK fusions, or ROS1 fusions[1][9]. The metronomic approach involves frequent administration of lower doses of chemotherapy. 2. **HER2-Negative Advanced Cancer**: Another trial investigated the combination of camrelizumab with vinorelbine and cisplatin for HER2-negative advanced cancer[3]. 3. **Triple-Negative Breast Cancer**: The combination has been studied in metastatic triple-negative breast cancer, comparing it with other chemotherapy regimens[4]. ## Administration Protocol In the elderly NSCLC trial, patients received: - Camrelizumab (200mg, Day 1, every 3 weeks) - Metronomic oral vinorelbine (30mg, three times weekly, on days 1, 3, and 5 of each week) for 6 cycles - Followed by camrelizumab monotherapy maintenance until disease progression or intolerable side effects[1] ## Safety Profile The combination therapy appears to have a manageable safety profile, though specific details about adverse events in the camrelizumab plus vinorelbine combination are limited in the provided search results. However, in other camrelizumab-based combinations, treatment-related adverse events were generally manageable[2]. This combination represents an emerging approach in cancer treatment, particularly for elderly patients or those who may not tolerate more aggressive platinum-based chemotherapy regimens.